The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective

Table 1

Utility values and selected costs.

Input	Value
Health state utility values
Progression-free	0.745
Progressed	0.678
Drug therapy costs (per cycle)
Lenvatinib	$2,142
Sorafenib	$4,320
Medical resource use costs (per cycle)
Physician visits (progression-free)	$176
Physician visits (progressed)	$187
Laboratory tests (progression-free)	$29
Laboratory tests (progressed)	$23
Radiological tests (progression-free)	$131
Radiological tests (progressed)	$79
Hospitalisation (progression-free)	$27
Hospitalisation (progressed)	$80
Adverse event management costs (per event)
Aspartate aminotransferase increased	$443
Asthenia	$1,879
Blood bilirubin increased	$1,954
Diarrhea	$384
Fatigue	$452
Gamma-glutamyl transferase increased	$418
Hypertension	$482
Palmar-plantar erythrodysesthesia	$418
Platelet count decreased	$418
Proteinuria	$418
Weight decreased	$1,845
Other costs
Mortality cost (applied at time of death)	$31,583